Актуальные аспекты применения макролидов при беременности и лактации | КМАХ

Актуальные аспекты применения макролидов при беременности и лактации

Клиническая Микробиология и Антимикробная Химиотерапия. 2010; 12(1):41-53

​ Стецюк О.У., Андреева И.В.
беременность лактация макролиды безопасность нежелательные лекарственные реакции
Раздел
Антимикробные препараты
Тип
Журнальная статья
Публикация
Клиническая Микробиология и Антимикробная Химиотерапия. 2010; 12(1):41-53

Аннотация

В обзоре представлены некоторые общие аспекты применения антибактериальных препаратов во время беременности, а также рассмотрены современные данные по безопасности применения макролидов при беременности и лактации, отдельные показания для терапевтического и профилактического использования данной группы препаратов в акушерской практике, определены перспективные направления дальнейших исследований в этой области.

  • 1. Romero R., Espinoza J., Chaiworapongsa T., Kalache K. Infection and prematurity and the role of preventive strategies. Semin Neonatol 2002; 7:259-74.
  • 2. Рекомендации по ведению больных с инфекциями почек, мочевых путей и мужских половых органов Европейской урологической ассоциации. К. Набер, М.С. Бишоп, Т.Е. Бйерклунд-Йохансен [и др.]: пер. с англ. - М., 2008. - 223 с.
  • 3. Чилова Р.Я., Ищенко А.И., Рафальский В.В. Особенности применения антимикробных препаратов при беременности. Клиническая Микробиология и Антимикробная Химиотерапия 2005; 7:77-89.
  • 4. Andrade S.E., Gurwitz J.H., Davis R.L., et al. Prescription drug use in pregnancy. Am J Obstet Gynecol 2004; 191:398-407.
  • 5. Splinter M.Y., Sagraves R., Nightengale B., Rayburn W.F. Prenatal use of medications by women giving birth at a university hospital. South Med J 1997; 90:498-502.
  • 6. Aviv R.I., Chubb K., Lindow S.W. The prevalence of maternal medication ingestion in the antenatal period. S Afr Med J 1993; 83:657-60.
  • 7. De Vigan C., De Walle H.E., Cordier S., et al. Therapeutic drug use during pregnancy: a comparison in four European countries. OECM Working Group. Occupational Exposures and Congenital Anomalies. J Clin Epidemiol 1999; 52:977-82.
  • 8. de Jong P.C., Nijdam W.S., Zielhuis G.A., Eskes T.K. Medication during low-risk pregnancy. Eur J Obstet Gynecol Reprod Biol 1991; 41:191-6.
  • 9. Buitendijk S., Bracken M.B. Medication in early pregnancy: prevalence of use and relationship to maternal characteristics. Am J Obstet Gynecol 1991; 165:33-40.
  • 10. Headley J., Northstone K., Simmons H., Golding J.; ALSPAC Study Team. Medication use during pregnancy: data from the Avon Longitudinal Study of Parents and Children. Eur J Clin Pharmacol 2004; 60:355-61.
  • 11. Villanueva LA, Martinez Ayala H, Garcia Lara E. Drug consumption during pregnancy. Ginecol Obstet Mex 1998; 66:423-7.
  • 12. Olesen C., Steffensen F.H., Nielsen G.L., de Jong-van den Berg L., Olsen J., Sorensen H.T. Drug use in first pregnancy and lactation: a population-based survey among Danish women. The EUROMAP group. Eur J Clin Pharmacol 1999; 55:139-44.
  • 13. Стриженок Е.А. Фармакоэпидемиология лекарственных средств у беременных. Автореф. дисс. канд. мед. наук. Смоленск, 2005.
  • 14. Shehata H, Nelson-Piercy C. Drugs to avoid. Best Pract Res Clin Obstet Gynaecol 2001; 15:971-86.
  • 15. McKeever T.M., Lewis S.A., Smith C., Hubbard R. The importance of prenatal exposures on the development of allergic disease:a birth cohort study using the west midlands general practice database. Am J Respir Crit Care Med 2002; 166:827-32.
  • 16. Bizzarro M.J., Dembry L.M., Baltimore R.S., Gallagher P.G. Changing patterns in neonatal Escherichia coli sepsis and ampicillin resistance in the era of intrapartum antibiotic prophylaxis. Pediatrics 2008; 121:689-96.
  • 17. Alarcon A., Peсa P., Salas S., Sancha M., Omeсaca F. Neonatal early onset Escherichia coli sepsis: trends in incidence and antimicrobial resistance in the era of intrapartum antimicrobial prophylaxis. Pediatr Infect Dis J 2004; 23:295-9.
  • 18. Ушкалова Е.А. Лекарственные средства и беременность. Фарматека 2003; 2(65).
  • 19. Stika C.S., Frederiksen M.C. Drug therapy in pregnant and nursing women. In: Atkinson AJ, editor. Principles of clinical pharmacology. San Diego (CA): Academic Press, 2001.
  • 20. Philipson A., Sabath L.D., Charles D. Erythromycin and clindamycin absorption and elimination in pregnant women. Clin Pharmacol Ther 1976; 19:68-77.
  • 21. Reynolds F., Knott C. Pharmacokinetics in pregnancy and placental drug transfer. Oxf Rev Reprod Biol 1989; 11:389-449.
  • 22. Mucklow J.C. The fate of drugs in pregnancy. Clin Obstet Gynaecol 1986; 13:161-75.
  • 23. Pacifici G.M. Placental transfer of antibiotics administered to the mother: a review. Int J Clin Pharmacol Ther 2006; 44:57-63.
  • 24. Sa del Fiol F., Gerenutti M., Groppo F.C. Antibiotics and pregnancy. Pharmazie. 2005; 60:483-93.
  • 25. Miller E.L. The penicillins: a review and update. J Midwifery Womens Health 2002; 47:426-34.
  • 26. Cavenee M.R., Farris J.R., Spalding T.R., at al. Treatment of gonorrhea in pregnancy. Obstet Gynecol 1993; 81:33-8.
  • 27. Friese K. Antibiotic therapy in pregnancy (article in German). Immun Infekt 1993; 21:111-4.
  • 28. Leophonte P. Antibiotics during pregnancy and breast feeding: consequences for the treatment of respiratory infections. Rev Mal Respir 1988; 5:293-8.
  • 29. Garland S.M, O’Reilly M.A. The risks and beneWts of antimicrobial therapy in pregnancy. Drug Saf 1995; 13:188-205.
  • 30. Ellegard E.K. Clinical and pathogenetic characteristics of pregnancy rhinitis. Clin Rev Allergy Immunol. 2004; 26:149-59.
  • 31. Heikkila A., Erkkola R. Review of beta-lactam antibiotics in pregnancy. The need for adjustment of dosage schedules. Clin Pharmacokinet 1994; 27:49-62.
  • 32. Di Lorenzo G., Mansueto P., Melluso M., et al. Allergy in pregnancy (article in Italian). Clin Ter 1994; 145:223-9.
  • 33. Schatz M. The efficacy and safety of asthma medications during pregnancy. Semin Perinatol 2001; 25:145-52.
  • 34. Ambro B.T., Scheid S.C., Pribitkin E.A. Prescribing guidelines for ENT medications during pregnancy ENT J 2003; 82:565-8.
  • 35. Brocklehurst P. Antibiotics for gonorrhoea in pregnancy. Cochrane Database Syst Rev 2002:CD000098.
  • 36. Bryskier A. Antimicrobial Agents. Antibacterials and Antifungals. ASM Press. Washington, USA, 2005.
  • 37. Жаркова Л.П., Ушкалова Е.А., Карпов О.И. Применение антиинфекционных препаратов при беременности и кормлении грудью. Практическое руководство по антиинфекционной химиотерапии. Страчунский Л.С., Белоусов Ю.Б., Козлов С.Н., ред. Смоленск: МАКМАХ, 2007 г. С. 423-34.
  • 38. Государственный реестр лекарственных средств Российской Федерации. Типовые клинико-фармакологические статьи. http://www.regmed.ru/search.asp
  • 39. Heikkinen T., Laine K., Neuvonen P.J., Ekblad U. The transplacental transfer of the macrolide antibiotics erythromycin, roxithromycin and azithromycin. BJOG 2000; 107:770-5.
  • 40. McCormack W.M., George H., Donner A. Hepatotoxicity of erythromycin estolate during pregnancy. AntiMicrob Agents Chemother 1977; 12:630-5.
  • 41. Heinonen O.P., Sloane D., Shapiro S. Birth defects and drugs in pregnancy. Littleton (MA): Publishing Sciences Group, 1977:435.
  • 42. Czeizel A.E., Rockenbauer M., Sorensen H.Y., Olsen J. A population-based case-control teratologic study of oral erythromycin treatment during pregnancy. Reprod. Toxicol 1999; 13:531-6.
  • 43. Kallen B.A.J., Otterblad Olausson P., Danielsson B.R. Is erythromycin therapy teratogenic in humans? Reprod Toxicol 2005; 20:209-14.
  • 44. Volberg W.A., Koci B.J., Su W., et al. Blockade of human cardiac potassium channel human ether-a-go-go-related gene (HERG) by macrolide antibiotics. J Pharmacol Exp Ther 2002; 302:320-7.
  • 45. Юрьев С.Ю, Евтушенко И.Д., Огородова Л.М. Определение концентрации азитромицина в хориальной ткани в первом триместре беременности. Антибиот и химиотер 2004; 49:10-2.
  • 46. Stray-Pederson В. The European Research Network on Congenital Toxoplasmosis Treatment Group. Azithromycin levels in placental tissue, amniotic fluid and blood. In: The 36th Interscience Conference on Antimicrobial Agents and Chemotherapy. New Orleans, 1996, abstr. A68.
  • 47. Ramsey P.S., Vaules M.B., Vasdev G.M., et al. Maternal and transplacental pharmacokinetics of azithromycin. Am J Obstet Gynecol 2003; 188:714-718.
  • 48. DeMott K. Azithromycin commonly used in pregnancy. International Medical News Group 2002. http://findarticles.com/p/articles/mi_m0CYD/is_20_37/ai_ 93531959?tag=artBody; col1
  • 49. McGregor J.A., Hager W.D., Gibbs R.S., et al. Assessment of office-based care of sexually transmitted diseases and vaginitis and antibiotic decision-making by obstetriciangynecologists. Infect Dis Obstet Gynecol 1998; 6:247-51.
  • 50. Sarkar M., Woodland C.C., Koren G., Einarson A.R.N. Pregnancy outcome following gestational exposure to azithromycin. BMC Pregnancy Childbirth 2006; 6:18.
  • 51. Ogasawara K.K., Goodwin T.M. Efficacy of azithromycin in reducing lower genital Ureaplasma urealyticum colonization in women at risk for preterm delivery. J Matern Fetal Med 1999; 8:12-6.
  • 52. Choi E.K., Pai H. Azithromycin therapy for scrub typhus during pregnancy. Clin Infect Dis 1998; 27:1538-9.
  • 53. Simunic V., Vrcic H., Culig J., et al. Single dose of azithromycin in the treatment of sexually transmitted disease in infertile and pregnant women. In: The 3rd International Conference on the Macrolides, Azalides and Streptogramins. Lisbon, 1996: abstr. 2.21.
  • 54. Jacobson G.F., Autry A.M., Kirby R.S., et al. A randomized controlled trial comparing amoxicillin and azithromycin for the treatment of Chlamydia trachomatis in pregnancy. Am J Obstet Gynecol 2001; 184:1352-4.
  • 55. Adair C.D., Gunter M., Stovall T.G., et al. Chlamydia in pregnancy: a randomized trial of azithromycin and erythromycin. Obstet Gynecol 1998; 91:165-8.
  • 56. Edwards M.S., Newman R.B., Carter S.G., et al. Randomized clinical trial of azithromycin vs erythromycin for the treatment of Chlamydia cervicitis in pregnancy. Infect Dis Obstet Gynecol 1997; 4:333-7.
  • 57. Rahangdale L., Guerry S., Bauer H.M. et al. An observational cohort study of Chlamydia trachomatis treatment in pregnancy. Sex. Transm. Dis. 2006; 33: 106-10.
  • 58. Wilton L.V., Pearce G.L., Martin R.M., et al. The outcomes of pregnancy in women exposed to newly marketed drugs in general practice in England. Br. J. Obstet. Gynaecol. 1998; 105: 882-9.
  • 59. Amsden G.W. Erythromycin, clarithromycin, and azithromycin: are the differences real? Clin Ther. 1996; 18:56-72.
  • 60. Biaxin (Clarithromycin). Product Information. Rx List. Internet Drug Index. http://www.rxlist.com/biaxindrug.htm
  • 61. Witt A., Sommer E.M., Cichna M., et al. Placental passage of clarithromycin surpasses other macrolide antibiotics. Am J Obstet Gynecol 2003; 188:816-9.
  • 62. Einarson A., Philips E., Mawje F., et al. A prospective controlled study of clarithromycin in pregnancy. Am J Perinatol 1998; 15:523-5.
  • 63. Chun J.Y., Han J.Y., Ahn H.K., et al. Fetal outcome following roxithromycin exposure in early pregnancy. J Matern Fetal Neonatal Med 2006; 19(3):189-92.
  • 64. Farhat C.K., Calvalho L.H.F.R., Chung S.S., et al. Toxoplasmosis II. J Pediatr 1981; 51:344-7.
  • 65. Gratzl R., Sodeck G., Platzer P., e.a. Treatment of toxoplasmosis in pregnancy: concentrations of spiramycin and neospiramycin in maternal serum and amniotic fluid. Eur J Clin Microbiol Infect Dis 2002; 21:12-6.
  • 66. Desmonts G., Couvreur J. Congenital toxoplasmosis: a prospective study of 378 pregnancies. N Engl J Med. 1974; 50:1110-6.
  • 67. Carter A.O., Frank J.W. Congenital toxoplasmosis: epidemiological features and control. Can Med Assoc J 1986; 135:618-23.
  • 68. Desmonts G., Daffos F., Forrestier F., et al. Prenatal diagnosis of congenital toxoplasmosis. Lancet 1985; I:500-4.
  • 69. Fedele L., Acaia B., Marchini M., et al. Treatment of Chlamydia trachomatis endometritis with josamycin. J Chemother 1989; 1(4 Suppl):911-2.
  • 70. Czeizel A.E., Rockenbauer M., Olsen J., Sшrensen H.T. A case-control teratological study of spiramycin, roxithromycin, oleandomycin and josamycin. Acta Obstet Gynecol Scand 2000; 79:234-7.
  • 71. Charles P., Stumpf P., Buffet P., et al. Two unusual glandular presentations of tick-borne tularemia. Med Mal Infect 2008; 8:159-61.
  • 72. Khrianin AA, Reshetnikov OV. Is it safe to use josamycin in the obstetrics practice in Russia? Antibiot Khimioter 2007; 52:32-6.
  • 73. Решетников О.В., Хрянин А.А. Макролиды в лечении хламидийной инфекции у беременных (эффективность, безопасность, экономичность). Русский медицинский журнал 2008; 16:23-7.
  • 74. Никонов А.П., Чилова Р.А., Остроумова М.В. и соавт. Применение азитромицина при лечении хламидийной инфекции у беременных женщин. Гинекология 2009; 11:14-7.
  • 75. Monga M., Blanco J.D. Intrauterine infection and preterm labor. Infect Dis Obstet Gynecol 1995; 3:37-44.
  • 76. Duff P. Maternal and perinatal infections. In: Gabbe S.G., Niebyl J.R., Simpson J.L., eds. Obstetrics: Normal& Problem Pregnancies, 3d ed. New York: Churchill Livingstone; 1996.
  • 77. Kenyon S.L., Taylor D.J., Tarnow-Mordi W. ORACLE Collaborative Group. Broad-spectrum antibiotics for preterm, prelabour rupture of fetal membranes: the ORACLE I randomised trial. ORACLE Collaborative Group. Lancet 2001; 357:979-88.
  • 78. Kenyon S.L., Taylor D.J., Tarnow-Mordi W. ORACLE Collaborative Group. Broad-spectrum antibiotics for spontaneous preterm labour: the ORACLE II randomised trial. ORACLE Collaborative Group. Lancet 2001; 357:989-94.
  • 79. Kenyon S., Boulvain M., Neilson J. Antibiotics for preterm rupture of membranes. Cochrane Database of Systematic Reviews 2007, Issue 4. Art. No.: CD001058.
  • 80. Yudin M.H., van Schalkwyk J., Van Eyk N., et al. Antibiotic therapy in preterm premature rupture of the membranes. J Obstet Gynaecol Can 2009; 31:863-74.
  • 81. Mahon B.E., Rosenman M.B., Kleiman M.B. Maternal and infant use of erythromycin and other macrolide antibiotics as risk factors for infantile hypertrophic pyloric stenosis. J Pediatr 2001; 139:380-4.
  • 82. Kenyon S., Pike K., Jones D.R., et al. Childhood outcomes after prescription of antibiotics to pregnant women with preterm rupture of the membranes: 7-year follow-up of the ORACLE I trial. Lancet 2008;372:1310-8.
  • 83. Kenyon S., Pike K., Jones D.R., et al. Childhood outcomes after prescription of antibiotics to pregnant women with spontaneous preterm labour: 7-year follow-up of the ORACLE II trial. Lancet 2008; 372:1319-27.
  • 84. Tita A.T., Rouse D.J., Blackwell S., et al. Emerging concepts in antibiotic prophylaxis for cesarean delivery: a systematic review. Obstet Gynecol 2009; 113:675-82.
  • 85. Owens S.M., Brozanski B.S., Meyn L.A., Wiesenfeld H.C. Antimicrobial prophylaxis for cesarean delivery before skin incision. Obstet Gynecol 2009; 114:573-9.
  • 86. Costantine M.M., Rahman M., Ghulmiyah L., et al. Timing of perioperative antibiotics for cesarean delivery: a metaanalysis. Am J Obstet Gynecol 2008; 199:301.e1-6.
  • 87. Tita A.T., Owen J., Stamm A.M., et al. Impact of extended-spectrum antibiotic prophylaxis on incidence of postcesarean surgical wound infection. Am J Obstet Gynecol 2008; 199:303.e1-3.
  • 88. Tita A.T., Hauth J.C., Grimes A., et al. Decreasing incidence of postcesarean endometritis with extendedspectrum antibiotic prophylaxis. Obstet Gynecol 2008; 111:51-6.
  • 89. Work Group on Breast-feeding, American Academy of Pediatrics. Breast-feeding and the use of human milk. Pediatrics 1997; 100:1035-9.
  • 90. Wright A.L., Holberg C.J., Taussig L.M., et al. Relationship of infant feeding to recurrent wheezing at age 6 years. Arch Pediatr Adolesc Med 1995; 149:758-63.
  • 91. Aniansson G., Alm B., Andersson B., et al. A prospective cohort study on breast-feeding and otitis media in Swedish infants. Pediatr Infect Dis J 1994; 13:183-8.
  • 92. Hylander M.A., Strobino D.M., Dhanireddy R. Human milk feedings and infection among very low birth weight infants. Pediatrics 1998; 102:E38.
  • 93. Labbok M.H. Health sequelae of breast-feeding for the mother. Clin Perinatol 1999; 26:491-503.
  • 94. Briggs G.G, Freeman R.K., Yaffe S.J. Drugs in pregnancy and lactation. 5th ed. Baltimore (MD): Williams & Wilkins, 1998.
  • 95. Stang H. Pyloric stenosis associated with erythromycin ingested through breast milk. Minn Med 1986; 69:669- 70.
  • 96. American Academy of Pediatrics. The transfer of drugs and other chemicals into human milk. Pediatrics 2001; 108:776-89.
  • 97. Sedlmayr T., Peters F., Raasch W., et al. Clarithromycin, a new macrolide antibiotic: effectiveness in puerperal infections and pharmacokinetics in breast milk. Geburtshilfe Frauenheilkd. 1993; 53(7):488-91.
  • 98. Kelsey J.J., Moser L.R., Jennings J.C., et al. Presence of azithromycin breast milk concentration: a case report. Am J Obstet Gynecol 1994; 170:1375-6.
  • 99. Bar-Oz B., Bulkowstein M., Benyamini L., et al. Use of antibiotic and analgesic drugs during lactation. Drug Saf 2003; 26:925-35.
  • 100. Goldstein L.H., Berlin M., Tsur L., et al. The safety of macrolides during lactation. Breastfeed Med 2009; 4:197-200.
  • 101. Sørensen H.T., Skriver M.V., Pedersen L., et al. Risk of infantile hypertrophic pyloric stenosis after maternal postnatal use of macrolides. Scand J Infect Dis 2003; 35:104-6.
Просмотров
0 Аннотация
0 PDF
0 Цитирования
Поделились